Result of AGM

RNS Number : 3761C
Ergomed plc
27 June 2016
 

 

Results of 2016 Annual General Meeting

 

 

 

 

Enquiries:

 

Stifel Nicolaus Europe Limited

Tel:  +44 (0) 20 7710 7600

(Nominated Adviser and Joint Broker)

Jonathan Senior / Stewart Wallace




Numis

Tel: +44 (0) 20 7260 1000

(Joint Broker)

Michael Meade / James Black




FTI Consulting

Tel:  +44 (0) 20 3727 1000

Simon Conway / Mo Noonan


 

 

About Ergomed

 

Founded in 1997, Ergomed plc is a profitable UK-based company, providing drug development services to the pharmaceutical industry and has a growing portfolio of co-development partnerships. It operates in over 50 countries.

 

Ergomed provides clinical development, trial management and pharmacovigilance services to over 100 clients ranging from top 10 pharmaceutical and generics companies to small and mid-sized drug development companies. Ergomed successfully manages clinical development from Phase I through to late phase programmes.

 

Ergomed has wide therapeutic expertise, with a particular focus in oncology, neurology and immunology and the development orphan drugs. Ergomed's approach to clinical trials is differentiated from that of other providers by its innovative Study Site Management model and the use of Study Physician Teams, resulting in a close relationship between Ergomed and the physicians involved in clinical trials.

 

As well as providing high quality clinical development services, Ergomed is building a portfolio of co-development partnerships with pharma and biotech companies. Here Ergomed shares the risks and rewards of drug development, leveraging its expertise and services in return for carried interest in the drugs under development. - a low risk investment model for potential high returns. For further information, visit: http://ergomedplc.com.

 

Global pharmacovigilance and medical information services are provided through its group company PrimeVigilance. www.primevigilance.com. PrimeVigilance is a specialised pharmacovigilance and medical information services provider positioned between the large clinical trials focused CROs and the smaller, local service providers who do not have the expertise or international presence needed for accurate, international safety and medical information services. 

 


This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
RAGLLFEFRSIDFIR

Companies

Ergomed (ERGO)
UK 100

Latest directors dealings